Figure 6.

rBCG::PGL-I targeting CR3 triggers Syk and NFATc in vivo. (A,B) WT and itgam^−/− mice were nasally infected with 5 × 10⁶ CFUs of fluorescent rBCG::PGL-I or rBCG::noPGL, and received two nasal doses of Syk inhibitor GS-9973 administered 1 h before and after bacteria. BAL and lung tissues were harvested 24 h later to analyze cells by flow cytometry. (A,B) Numbers of Ly-6G⁺, CD11c⁻ PMNs and Ly-6G⁻, CD11c⁺ MPs harboring BCG-EGFP⁺ recovered from the lung parenchyma from 11 individuals (A) or BAL from 12 individuals pooled per 2 (B). (C) IL-10 produced in situ by lung cells was analyzed by ELISA in the first BAL from 12 individuals pooled per 2. (D) WT mice received two nasal doses of CsA 1 h before and 1 h after rBCG::PGL-I or rBCG::noPGL inhalation, to block NFATc translocation. IL-10 produced in situ by lung cells was analyzed as in (C). Data are represented as individual values from n = 11 (A) or n = 6 (B–D) from two independent experiments. ^**P < 0.01; ^***P < 0.001.